Compare · MDCX vs NVO
MDCX vs NVO
Side-by-side comparison of Medicus Pharma Ltd. (MDCX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDCX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 28202.6x MDCX ($6.2M).
- Over the past year, MDCX is down 97.2% and NVO is down 28.6% - NVO leads by 68.6 points.
- MDCX has been more active in the news (7 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for MDCX).
- Company
- Medicus Pharma Ltd.
- Novo Nordisk A/S
- Price
- $3.31+5.41%
- $38.82-1.05%
- Market cap
- $6.2M
- $173.66B
- 1M return
- -61.93%
- -10.14%
- 1Y return
- -97.17%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MDCX
- SEC Form 424B3 filed by Medicus Pharma Ltd.
- SEC Form 8-K filed by Medicus Pharma Ltd.
- Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
- SEC Form 424B3 filed by Medicus Pharma Ltd.
- SEC Form 8-K filed by Medicus Pharma Ltd.
- Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
- Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
- SEC Form SCHEDULE 13D filed by Medicus Pharma Ltd.
- SEC Form 424B3 filed by Medicus Pharma Ltd.
- Medicus Pharma Ltd. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank